In-hospital antimicrobial use and multidrug-resistant infections among COVID-19 patients in Northern Malaysia (COVAM): a multicentre study.

IF 2.6 Q1 HEALTH POLICY & SERVICES
Journal of Pharmaceutical Policy and Practice Pub Date : 2026-09-28 eCollection Date: 2026-01-01 DOI:10.1080/20523211.2026.2728836
Kah Shuen Thong, Chii-Chii Chew, Meng Fei Cheah, E-Li Leong, Chee Tao Chang, Jason Choong Yin Lee, Philip Rajan Devesahayam, Hong Bee Ker, Jeyaseelan P Nachiappan, Zaiton Kamarruddin, Lay Ming Ding
{"title":"In-hospital antimicrobial use and multidrug-resistant infections among COVID-19 patients in Northern Malaysia (COVAM): a multicentre study.","authors":"Kah Shuen Thong, Chii-Chii Chew, Meng Fei Cheah, E-Li Leong, Chee Tao Chang, Jason Choong Yin Lee, Philip Rajan Devesahayam, Hong Bee Ker, Jeyaseelan P Nachiappan, Zaiton Kamarruddin, Lay Ming Ding","doi":"10.1080/20523211.2026.2728836","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>During the COVID-19 pandemic, empirical antimicrobials were frequently prescribed despite low documented rates of bacterial and fungal co-infections. While early pandemic data exist, evidence evaluating antimicrobial consumption and multidrug-resistant organism (MDRO) dynamics during subsequent pandemic surges remains limited. This study evaluated antimicrobial receipt, associated factors, and the prevalence of MDROs among hospitalised COVID-19 patients in Northern Malaysia.</p><p><strong>Methods: </strong>This multicentre retrospective observational cohort study included adults (≥18 years) with confirmed COVID-19 admitted to ten government hospitals in Northern Malaysia between February 2020 and December 2021. Among 19,116 admissions, 480 cases were sampled, yielding 476 eligible patients. Study outcomes included antimicrobial receipt and MDRO prevalence. Monthly antimicrobial days of therapy (DOT) per 1,000 patient-days were compared with state-level COVID-19 hospital admissions. Predictors were analysed using a Poisson Generalized Linear Mixed Model.</p><p><strong>Results: </strong>Antibiotics were prescribed to 167 patients (35.1%), accounting for 381 prescriptions, predominantly β-lactam/β-lactamase inhibitors (54.1%). Most were empirical (92.9%), largely among non-ICU patients (72.2%) with pneumonia (82.9%). Antifungals were used in 13 patients (2.7%; 15 prescriptions), mainly empirical echinocandins (60.0%), and predominantly in ICU settings (66.7%). MDROs were detected in 8.4% (10/119) of patients with cultured specimens, representing patient-level MDRO prevalence. A significant positive correlation was observed between DOT and admissions (r = 0.701, <i>p</i> < 0.001, 95% CI [0.37-0.87]). Severe/critical COVID-19 stage, diabetes mellitus, chronic obstructive pulmonary disease and chronic kidney disease were consistently associated with antimicrobial prescription. Longer hospital stays, elevated neutrophil and C-reactive protein levels, smoking, and pre-hospital steroid/immunosuppressant use were additional predictors.</p><p><strong>Conclusion: </strong>Antimicrobial use was predominantly empirical and influenced by disease severity and admission surges. Although MDRO detection remained low, severity-driven prescribing highlights the risk of unnecessary antimicrobial exposure during pandemic waves. These findings inform outbreak-responsive antimicrobial stewardship strategies and support antimicrobial utilisation surveillance to guide resource planning during future public health emergencies.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"19 1","pages":"2728836"},"PeriodicalIF":2.6000,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13629810/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Policy and Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/20523211.2026.2728836","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"HEALTH POLICY & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: During the COVID-19 pandemic, empirical antimicrobials were frequently prescribed despite low documented rates of bacterial and fungal co-infections. While early pandemic data exist, evidence evaluating antimicrobial consumption and multidrug-resistant organism (MDRO) dynamics during subsequent pandemic surges remains limited. This study evaluated antimicrobial receipt, associated factors, and the prevalence of MDROs among hospitalised COVID-19 patients in Northern Malaysia.

Methods: This multicentre retrospective observational cohort study included adults (≥18 years) with confirmed COVID-19 admitted to ten government hospitals in Northern Malaysia between February 2020 and December 2021. Among 19,116 admissions, 480 cases were sampled, yielding 476 eligible patients. Study outcomes included antimicrobial receipt and MDRO prevalence. Monthly antimicrobial days of therapy (DOT) per 1,000 patient-days were compared with state-level COVID-19 hospital admissions. Predictors were analysed using a Poisson Generalized Linear Mixed Model.

Results: Antibiotics were prescribed to 167 patients (35.1%), accounting for 381 prescriptions, predominantly β-lactam/β-lactamase inhibitors (54.1%). Most were empirical (92.9%), largely among non-ICU patients (72.2%) with pneumonia (82.9%). Antifungals were used in 13 patients (2.7%; 15 prescriptions), mainly empirical echinocandins (60.0%), and predominantly in ICU settings (66.7%). MDROs were detected in 8.4% (10/119) of patients with cultured specimens, representing patient-level MDRO prevalence. A significant positive correlation was observed between DOT and admissions (r = 0.701, p < 0.001, 95% CI [0.37-0.87]). Severe/critical COVID-19 stage, diabetes mellitus, chronic obstructive pulmonary disease and chronic kidney disease were consistently associated with antimicrobial prescription. Longer hospital stays, elevated neutrophil and C-reactive protein levels, smoking, and pre-hospital steroid/immunosuppressant use were additional predictors.

Conclusion: Antimicrobial use was predominantly empirical and influenced by disease severity and admission surges. Although MDRO detection remained low, severity-driven prescribing highlights the risk of unnecessary antimicrobial exposure during pandemic waves. These findings inform outbreak-responsive antimicrobial stewardship strategies and support antimicrobial utilisation surveillance to guide resource planning during future public health emergencies.

马来西亚北部(COVAM) COVID-19患者的住院抗微生物药物使用和多重耐药感染:一项多中心研究
背景:在2019冠状病毒病大流行期间,尽管细菌和真菌合并感染率较低,但仍经常开具经验性抗微生物药物。虽然存在早期大流行数据,但评估随后大流行期间抗菌素消费和耐多药生物动态的证据仍然有限。本研究评估了马来西亚北部住院的COVID-19患者的抗微生物药物使用情况、相关因素和耐多药耐药发生率。方法:这项多中心回顾性观察队列研究纳入了2020年2月至2021年12月期间在马来西亚北部10家政府医院确诊的COVID-19成年人(≥18岁)。在19116例入院患者中,抽样了480例,产生了476例符合条件的患者。研究结果包括抗菌药物的使用情况和MDRO的流行情况。将每1000个患者日的月抗菌药物治疗天数(DOT)与国家级COVID-19住院人数进行比较。预测因子采用泊松广义线性混合模型进行分析。结果:使用抗生素167例(35.1%),占381张处方,以β-内酰胺/β-内酰胺酶抑制剂为主(54.1%)。大多数是经验性的(92.9%),主要是肺炎(82.9%)的非icu患者(72.2%)。13例患者(2.7%;15张处方)使用抗真菌药物,主要是经验性棘白菌素(60.0%),主要是在ICU环境(66.7%)。8.4%(10/119)的培养标本中检测到MDRO,代表了患者水平的MDRO患病率。DOT与住院人数呈显著正相关(r = 0.701, p)。结论:抗菌药物的使用主要是经验性的,并受疾病严重程度和住院人数的影响。尽管MDRO的检出率仍然很低,但严重程度驱动的处方突出了在大流行期间不必要的抗微生物药物暴露的风险。这些发现为应对疫情的抗菌素管理战略提供了信息,并支持对抗菌素利用情况进行监测,以指导未来突发公共卫生事件期间的资源规划。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Pharmaceutical Policy and Practice
Journal of Pharmaceutical Policy and Practice Health Professions-Pharmacy
CiteScore
4.70
自引率
9.50%
发文量
81
审稿时长
14 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书